Sugi Predict

Sugi Predict / Compounds / SCHEMBL14995348

SCHEMBL14995348

SCHEMBL14995348

Cn1c(=O)n(C)c2cc(Cl)c(N)cc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATAD2 Q6PL18 1/20 0.62
▸ S100B P04271 1/20 0.56
▸ MAPT P10636 2/20 0.44
▸ TP53 P04637 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ HSD17B10 Q99714 5/20 0.43
▸ HTT P42858 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ BRD4 O60885 2/20 0.42
▸ BRPF1 P55201 2/20 0.42
▸ GRIA1 P42261 1/20 0.38
▸ GRIA2 P42262 1/20 0.38
▸ GRIA3 P42263 1/20 0.38
▸ GRIA4 P48058 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CASP1 P29466 1/20 0.37
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30349855 1.00 ATAD2 (0.62) ATAD2S100BMAPTTP53GAA
SCHEMBL16771511 0.77 ATAD2 (1.00) ATAD2S100BMAPTTP53HSD17B10
SCHEMBL6745385 0.77 ATAD2 (0.64) ATAD2S100BMAPTTP53GAA
SCHEMBL19644300 0.75 ATAD2 (0.47) ATAD2S100BTP53HSD17B10HTT
SCHEMBL17534190 0.75 ATAD2 (0.68) ATAD2S100BMAPTTP53HSD17B10
SCHEMBL16736495 0.75 ATAD2 (0.62) ATAD2S100BMAPTTP53GAA
SCHEMBL1843229 0.72 ALDH1A1 (0.56) ATAD2S100BMAPTTP53GAA
SCHEMBL26654511 0.72 S100B (0.62) ATAD2S100BMAPTTP53GAA
SCHEMBL1115716 0.72 SIGMAR1 (0.40) ATAD2MAPTTP53GAAHSD17B10
SCHEMBL1115715 0.72 PKM (0.41) TP53GAAHPGDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590066-B2 Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 — — US disclosed
US-20230295095-A1 NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-09-21 — — US disclosed
EP-4169905-A1 NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF Korea Institute of Science and Technology (KR) 2023-04-26 — — EP disclosed
CN-115867277-A Novel fused heterocyclyl-carbohydrazone acyldinitrile compounds and use thereof 韩国科学技术研究院 2023-03-28 — — CN disclosed
WO-2021256899-A1 NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF 한국과학기술연구원 2021-12-23 — — WO disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
WO-2017162661-A1 1H-BENZO[DE]ISOQUINOLINE-1,3(2H)-DIONES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-28 — — WO disclosed
WO-2017162661-A1 1H-BENZO[DE]ISOQUINOLINE-1,3(2H)-DIONES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-28 — — WO disclosed
US-8796296-B2 Aminopyrimidine derivatives as LRRK2 modulators GENENTECH, INC. (US) 2014-08-05 — — US disclosed
US-8796296-B2 Aminopyrimidine derivatives as LRRK2 modulators GENENTECH, INC. (US) 2014-08-05 — — US disclosed
CN-103958498-A Aminopyrimidine derivatives as LRRK2 modulators HOFFMANN LA ROCHE 2014-07-30 — — CN disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
US-20130158006-A1 AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS GENENTECH, INC. (US) 2013-06-20 — — US disclosed
US-20130158006-A1 AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS GENENTECH, INC. (US) 2013-06-20 — — US disclosed
US-20130158006-A1 AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS GENENTECH, INC. (US) 2013-06-20 — — US disclosed
WO-2013079505-A1 AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-06-06 — — WO disclosed
WO-2013079505-A1 AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-06-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158006-A1 AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS LRRK2, PARK7, PINK1 ATAD2 916/4885S100B 4696/4885MAPT 337/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK ATAD2 1947/4885S100B 3530/4885MAPT 470/4885
US-12590066-B2 Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CLIC1 ATAD2 4595/4885S100B 4723/4885MAPT 4672/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK ATAD2 1855/4885S100B 3483/4885MAPT 438/4885
US-20230295095-A1 NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF CBR3, DBF4, DDT ATAD2 4077/4885S100B 4221/4885MAPT 3518/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK ATAD2 1855/4885S100B 3483/4885MAPT 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.